2-(2-ethylphenylthio)benzyl alcohol | 125981-85-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(2-ethylphenylthio)benzyl alcohol
• 英文别名: [2-(2-Ethylphenyl)sulfanylphenyl]methanol
• CAS: 125981-85-3
• 化学式: C₁₅H₁₆OS
• 分子量: 244.357
• InChiKey: ALXPSBJCWSMXJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-ethylphenylthio)benzyl alcohol 在 氢氧化钾 、 氯化亚砜 作用下， 以 吡啶 、 乙醇 、 水 为溶剂， 反应 21.0h， 生成 2-(2-(2-ethylphenylthio)phenyl)acetic acid
  参考文献：
  名称：

  Cervena, Irena; Holubek, Jiri; Svatek, Emil, Collection of Czechoslovak Chemical Communications, 1989, vol. 54, # 7, p. 1955 - 1965

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙基苯硫酚 在 铜 氢氧化钾 、 红铝 作用下， 以 水 、 甲苯 、 苯 为溶剂， 反应 9.75h， 生成 2-(2-ethylphenylthio)benzyl alcohol
  参考文献：
  名称：

  Cervena, Irena; Holubek, Jiri; Svatek, Emil, Collection of Czechoslovak Chemical Communications, 1989, vol. 54, # 7, p. 1955 - 1965

  摘要：

  DOI：

文献信息

• INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
  申请人：Marsault Eric

  公开号：US20090240027A1

  公开（公告）日：2009-09-24

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及公式（I）的新型大环化合物及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及公式（I）的化合物，其为胃动素受体拮抗剂，并可用于治疗与该受体及运动功能障碍相关的疾病。
• PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
  申请人：Marsault Eric

  公开号：US20120165566A1

  公开（公告）日：2012-06-28

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及公式（I）的新型大环化合物及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及公式（I）的化合物，它们是蠕动素受体的拮抗剂，并且在治疗与该受体相关的疾病和蠕动功能障碍的方面是有用的。
• MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES
  申请人：Marsault Éric

  公开号：US20120270807A1

  公开（公告）日：2012-10-25

  The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

  本发明涉及新型大环化合物及其盐，它们能结合和/或抑制丝氨酸蛋白酶酶。本发明还涉及这些化合物的中间体，含有这些化合物的制药组合物以及使用这些化合物的方法。这些化合物可用于治疗和预防一系列疾病指标，包括增生性疾病，特别是那些以肿瘤转移为特征的疾病，炎症性疾病，皮肤和组织疾病，心血管疾病，呼吸系统疾病和病毒感染。
• METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES
  申请人：Marsault Éric

  公开号：US20120270769A1

  公开（公告）日：2012-10-25

  The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

  本发明涉及新型大环化合物及其盐，这些化合物与/或抑制丝氨酸蛋白酶酶的结合，并使用这些化合物的方法。本发明还涉及这些化合物的中间体、含有这些化合物的制药组合物以及使用它们的方法。这些化合物可用作治疗和预防一系列疾病指标的治疗剂，包括高增殖性疾病，特别是肿瘤转移、炎症性疾病、皮肤和组织疾病、心血管疾病、呼吸系统疾病和病毒感染。
• Processes for Intermediates for Macrocyclic Compounds
  申请人：Marsault Éric

  公开号：US20110245459A1

  公开（公告）日：2011-10-06

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及一种新型的大环化合物，其化学式为（I），以及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及化合物（I），其为胃动素受体拮抗剂，可用于治疗与该受体和/或运动功能障碍相关的疾病。